Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Wright

Vascular Surgery Jonesboro, AR Medical Doctor

NPI 1558576041 CMS profile 1062359

4802 E Johnson Ave, Jonesboro, AR 72405

Open in the dashboard

General payments

$28,301

324 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Wright of Jonesboro, AR is reported in the CMS Open Payments database as having received $28,301 across 324 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,568 62
2024 General $6,358 57
2023 General $7,550 74
2022 General $5,170 56
2021 General $1,776 36
2020 General $1,172 28
2019 General $707 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Wright
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Mark Wright were reported at $5,568. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Mark Wright Vascular Surgery median Middle half National median
2019 $707 $796 $226–$2,363 $163
2020 $1,172 $348 $118–$1,110 $114
2021 $1,776 $471 $158–$1,421 $132
2022 $5,170 $725 $222–$2,183 $149
2023 $7,550 $836 $257–$2,440 $160
2024 $6,358 $909 $252–$2,619 $164
2025 $5,568 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Endologix, Inc. $14,355 39 payments
  2. Medtronic, Inc. $5,956 86 payments
  3. Boston Scientific Corporation $3,114 73 payments
  4. Silk Road Medical, Inc. $883 19 payments
  5. Philips Electronics North America Corporation $725 11 payments
  6. W. L. Gore & Associates, Inc. $535 15 payments
  7. Penumbra, Inc. $487 16 payments
  8. Inari Medical, Inc. $482 6 payments
  9. Bard Peripheral Vascular, Inc. $405 9 payments
  10. Cardiovascular Systems Inc. $403 10 payments
  11. Other $957 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,565 300 payments
  2. Consulting Fee $7,500 8 payments
  3. Travel and Lodging $2,070 14 payments
  4. Education $166 2 payments
Products named General payments · program years 2019–2025
  1. AFX2 Bifurcated Endograft System $10,256 16 payments
  2. ENDURANT IIS $3,708 52 payments
  3. Alto Abdominal Stent Graft System $3,020 10 payments
  4. TurboHawk $1,375 13 payments
  5. ELUVIA $872 28 payments
  6. FLOWTRIEVER CATHETER, S $839 11 payments
  7. ENROUTE Transcarotid Stent $737 15 payments
  8. ENROUTE Transcarotid Neuroprotection System $737 15 payments
  9. AFX $565 4 payments
  10. HawkOne $510 11 payments
  11. Other $6,833 185 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

454

Median for Vascular Surgery: 122

Drug cost

$46,571

Median for Vascular Surgery: $14,135

Branded share of claims

77.1%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 42 $25,489
Eliquis Apixaban Brand 26 $17,808
Clopidogrel Clopidogrel Bisulfate Brand 136 $963
Naloxone Hcl Generic 15 $926
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 134 $843
Atorvastatin Calcium Generic 24 $171
Gabapentin Generic 21 $168
Doxycycline Hyclate Generic 11 $89
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 12 $53
Prednisone Generic 18 $42

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 107 billing codes

Paid by Medicare

$183,790

Medicare's payments for the services billed

Medicare patients

476

Average age 75

Services billed

1,539

216 women, 260 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 54%
Arthritis 54%
Diabetes 47%
Chronic kidney disease 35%
Heart failure 33%
COPD 33%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

324 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record